small molecule

JESDUVROQ

DAPRODUSTAT

Loss of exclusivityMarch 2038latest FDA-listed patent expiry

CompanyGLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND

Drug detail

Brand name	JESDUVROQ
Active ingredient	DAPRODUSTAT
Strength	4MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2023
Marketing status	DISCN

Listed patents

Patent	Expires	Type
11117871	March 2038	substance, product
11649217	March 2038	product
8324208	December 2028	substance, product
8815884	June 2027	product
8557834	June 2027	use U-1238
11643397	June 2027	substance

Regulatory exclusivity

Code	Expires
NCE	February 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND